Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time ...

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it’s ...

Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US patients at a discount. The Danish drugmaker launched NovoCare ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...

Novo Nordisk (NVO) is advancing 4% after the drug maker cut the price of its very popular weight-loss drug, Wegovy, by over 50%. Additionally, the company launched a new online pharmacy from which ...

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novo Nordisk stock rose rapidly early Friday after a study from the University of Oxford showed its diabetes and weight-loss drug, semaglutide, could lower the risk of developing dementia.

Even with the shortage, Novo Nordisk saw fourth-quarter Wegovy sales more than double to 19.9 billion Danish kroner ($2.9 billion), and full-year 2024 sales jumped 25% to $40.6 billion, driven by ...

SAN FRANCISCO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Novo Nordisk A/S (NYSE: NVO) is embroiled in a class-action lawsuit filed by investors who claim they were misled about the future of its ...

This collaboration unites Novo Nordisk’s deep therapeutic knowledge and drug development experience with Gensaic’s novel protein design technology with the aim to discover tissue targeting ...